Free Trial
NASDAQ:ENGN

enGene Q4 2024 Earnings Report

enGene logo
$3.68 +0.11 (+3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$3.76 +0.07 (+2.04%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Thursday, December 19, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

enGene's Q3 2025 earnings is scheduled for Wednesday, September 10, 2025, with a conference call scheduled on Tuesday, September 9, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

enGene Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN), through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

View enGene Profile

More Earnings Resources from MarketBeat